Small Molecule Videos

  1. PCI Capacity Update July 2025: Small Molecule Drug Product/Finished Dosage Form 7/29/2025

    Dr. Rebecca Coutts highlights PCI’s high potent oral solid dose (OSD) and oral liquid capabilities, focusing on site expertise, specialized infrastructure, and handling of complex molecules.

  2. Your Boutique CDMO Partner Of Choice 7/29/2025

    Lora Wallis and Chris Cuthbertson highlight Douglas CDMO’s strengths in high-potency softgels and liquids and the company's 67 years of expertise and a client-centric approach.

  3. Comprehensive CDMO Services From Clinical To Commercial Supply 7/29/2025

    From world-class facilities across North America and Asia, high-quality drug products are manufactured and supplied to over 100 global markets, supporting patient and healthcare needs.

  4. MilliporeSigma Capacity Update July 2025: Small Molecule Drug Substance/API 7/29/2025

    Applications specialist John Stevens shows how MilliporeSigma is using their 35+ years of CDMO experience and expertise to move customers’ small molecules forward to the clinic and beyond to commercialization.

  5. Amorphous Solid Dispersions: Pre-Clinical To Commercial Capabilities 7/29/2025

    ASDs continue to be an attractive option for progressing and commercializing poorly soluble compounds. This talk focuses on capabilities to screen the potential for ASDs in early phase studies as well as their commercial applicability.

  6. Your Integrated Drug Substance Partner 7/29/2025

    With capabilities to support your next small molecule drug substance program from R&D to commercial scale, learn about our integrated facilities, project teams, and available capacity.

  7. Aragen Capacity Update July 2025: Small Molecule Drug Substance/API 7/28/2025

    Explore specialized expertise in solving challenging small molecule formulation problems (poor solubility, bioavailability, complex delivery routes).

  8. Afton Scientific Capacity Update July 2025: Fill/Finish 7/28/2025

    Gain an overview of a new state-of-the-art Groninger filling line’s capabilities, production scale-up timelines, and how this new infrastructure supports product flexibility and long-term growth for our partners in the injectable drug product space.

  9. MilliporeSigma Capacity Update October 2025: ADC 7/28/2025

    MilliporeSigma and Simtra's streamlined collaboration encompasses every stage, including bioconjugation, linker and payload supplies, formulation development, and final fill/finish of drug substance.

  10. Integrated ADC Offering: From Concept To Commercialization 7/28/2025

    Leveraging deep ADC expertise and experience, successfully develop high quality, commercially viable processes, spanning from pre-clinical development through commercial scale manufacturing.